Ruby CE - Search Results

1

Signaling through OX40 enhances antitumor immunity.

Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, Li Y, Puri S, Poehlein CH, Morris N, Kovacsovics-Bankowski M, Moudgil T, Twitty C, Walker EB, Hu HM, Urba WJ, Weinberg AD, Curti B, Fox BA. Jensen SM, et al. Among authors: ruby ce. Semin Oncol. 2010 Oct;37(5):524-32. doi: 10.1053/j.seminoncol.2010.09.013. Semin Oncol. 2010. PMID: 21074068 Free PMC article. Review.

2

Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.

Ruby CE, Redmond WL, Haley D, Weinberg AD. Ruby CE, et al. Eur J Immunol. 2007 Jan;37(1):157-66. doi: 10.1002/eji.200636428. Eur J Immunol. 2007. PMID: 17183611 Free article.

3

OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.

Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD. Gough MJ, et al. Among authors: ruby ce. Cancer Res. 2008 Jul 1;68(13):5206-15. doi: 10.1158/0008-5472.CAN-07-6484. Cancer Res. 2008. PMID: 18593921 Free article.

4

OX40-enhanced tumor rejection and effector T cell differentiation decreases with age.

Ruby CE, Weinberg AD. Ruby CE, et al. J Immunol. 2009 Feb 1;182(3):1481-9. doi: 10.4049/jimmunol.182.3.1481. J Immunol. 2009. PMID: 19155495 Free PMC article.

5

The effect of aging on OX40 agonist-mediated cancer immunotherapy.

Ruby CE, Weinberg AD. Ruby CE, et al. Cancer Immunol Immunother. 2009 Dec;58(12):1941-7. doi: 10.1007/s00262-009-0687-6. Epub 2009 Mar 14. Cancer Immunol Immunother. 2009. PMID: 19288101 Free PMC article. Review.

6

The role of OX40-mediated co-stimulation in T-cell activation and survival.

Redmond WL, Ruby CE, Weinberg AD. Redmond WL, et al. Among authors: ruby ce. Crit Rev Immunol. 2009;29(3):187-201. doi: 10.1615/critrevimmunol.v29.i3.10. Crit Rev Immunol. 2009. PMID: 19538134 Free PMC article. Review.

7

IL-12 is required for anti-OX40-mediated CD4 T cell survival.

Ruby CE, Montler R, Zheng R, Shu S, Weinberg AD. Ruby CE, et al. J Immunol. 2008 Feb 15;180(4):2140-8. doi: 10.4049/jimmunol.180.4.2140. J Immunol. 2008. PMID: 18250420

8

Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right.

Ruby CE, Yates MA, Hirschhorn-Cymerman D, Chlebeck P, Wolchok JD, Houghton AN, Offner H, Weinberg AD. Ruby CE, et al. J Immunol. 2009 Oct 15;183(8):4853-7. doi: 10.4049/jimmunol.0901112. Epub 2009 Sep 28. J Immunol. 2009. PMID: 19786544 Free PMC article.

9

OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survival.

Vasilevsky NA, Ruby CE, Hurlin PJ, Weinberg AD. Vasilevsky NA, et al. Among authors: ruby ce. Eur J Immunol. 2011 Apr;41(4):1024-34. doi: 10.1002/eji.201040449. Epub 2011 Mar 14. Eur J Immunol. 2011. PMID: 21400495 Free PMC article.

10

Early-onset age-related changes in dendritic cell subsets can impair antigen-specific T helper 1 (Th1) CD4 T cell priming.

Farazi M, Cohn Z, Nguyen J, Weinberg AD, Ruby CE. Farazi M, et al. Among authors: ruby ce. J Leukoc Biol. 2014 Aug;96(2):245-54. doi: 10.1189/jlb.1A0114-066R. Epub 2014 Apr 8. J Leukoc Biol. 2014. PMID: 24714553

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters